PTX
Click for more information
2.44% 4.2¢ prescient therapeutics limited

CellPryme-M question

  1. reon1
    1,430 Posts.
    lightbulb Created with Sketch. 480
    clock Created with Sketch.
    11/06/22
    13:52
    Post #: 61956808
    Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?

    If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.

    Anyone able to answer this question? If not, I'll email the company.
    PTX Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

HIQ HITIQ's sensor-containing mouthguard OK'd by World Rugby specifications board
right-arrow Created with Sketch.
NEWS Talking Australia's very competitive property landscape: Realty Talks
right-arrow Created with Sketch.
AGY Argosy signs deal to sell battery-grade Rincon lithium to Korea
right-arrow Created with Sketch.
M2R Miramar sniffs 5.48% Cu, 54.4% Pb and 73.48g/t Ag at new WA prospect
right-arrow Created with Sketch.
ASL Andean discovers up to 4,649 AgEq through maiden drilling in Chile
right-arrow Created with Sketch.
EVN Evolution shares up 3% on quarterly results for June showing rise in gold production
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.2¢ 		Change
0.001(2.44%) 		Mkt cap ! $33.82M
Open High Low Value Volume
4.2¢ 4.3¢ 4.1¢ $23.91K 563.5K

Buyers (Bids)

No. Vol. Price($)
1 70733 4.2¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 24822 2
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.